BeiGene (NASDAQ:BGNE) reported quarterly losses of $(1.15) per share which beat the analyst consensus estimate of $(1.20) by 4.17 percent. The company reported quarterly sales of $1.00 billion which beat the analyst consensus estimate of $979.78 million by 2.23 percent. This is a 28.20 percent increase over sales of $781.31 million the same period last year.